<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html>
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <title>UCSC Ebola Portal</title>
    <link rel="stylesheet" href="../style/HGStyle.css" type="text/css">
    <link rel="stylesheet" href="../style/encodeProject.css" type="text/css">
    <link rel="stylesheet" href="ebolaPortal.css" type="text/css">
</head>

<body style="margin:0;">
    <!--#include virtual="../inc/ebola.topbar.html"-->
    <div class="header">
        <span class="txt">&nbsp; UCSC Ebola Genome Portal</span>
        <span class="subHeader">Resources for the 2014 West Africa Outbreak</span> 
    </div>
    <div style="margin:8px; margin-right:16px;">
        <table>
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
                <div class="bar"><h4 class="title">About</h4></div>
                <div class="content">
                <p>
                The 2014 Ebola epidemic in West Africa has stirred international response and
                renewed efforts to develop effective preventative and treatment options.
                In response to a request for help from vaccine researchers, we have fast-tracked
                the
                <a target="_blank" href="../cgi-bin/hgTracks?db=eboVir3">UCSC Ebola Genome Browser</a>
                built with viral sequences from previous outbreaks as
                well as the 2014 outbreak.  
		This site also provides related tools and 
                information that can be used to further the understanding of Ebola.</p>
                </div><!--end content-->
            
            </td>
            </tr>
            <!-- screenshot launchers 2x2 matrix -->
                <tr>

                    <!-- Browser image linking to browser CGI -->
                    <td>
                    <div style="margin-top:0; margin-left:10px; margin-right:10px" class="wrapper">
                    <div class="bar"><h4 class="title">Explore the Ebola Genome with the UCSC Browser</h4></div>
                        <div class="content">
                            <a href="../cgi-bin/hgTracks?db=eboVir3" target="_blank"><img class="screenshot" src="../images/ebolaBrowser.png"></a>
                        </div>
                    </div>
                    </td>

                    <!-- Incidence graph linked to CDC site -->
                    <td>
                    <div style="margin-top:0; margin-right: 10px;" class="wrapper">
                        <div class="bar"><h4 class="title">Learn about the 2014 outbreak</h4></div>
                            <a href="http://www.cdc.gov/vhf/ebola/" target="_blank"><img class="screenshot"  src="../images/Graph_Diseased_Ebola_2014.png"></a>
                    </div>
                    </td>

                    <!-- Viral structure cartoon and launcher from ViralZone -->
                    <td>
                    <div style="margin-top:0;" class="wrapper">
                        <div class="bar"><h4 class="title">Read about Ebola</h4></div>
                            <a href="http://viralzone.expasy.org/all_by_species/207.html" target="_blank"><img class="screenshot" src="../images/Filovirus_virion_small.png"></a>
                    </div>
                    </td>
                </tr>

<!-- Publications block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 15px; margin-left: 10px;" class="wrapper">
            <div class="bar"><h4 class="title">Related Publications and Data Resources</h4></div>
            <div class="content">
		<p>
  		PLOS Ebola Flipboard:  
        	<a href="https://flipboard.com/section/plos-ebola-collection-bRVgYj" 
		target="_blank">PLOS Ebola Collection</a> (all currently published articles, freely 
		available)
		</p>
		<p>
    		Science Magazine collection: 
        	<a href="http://www.sciencemag.org/site/extra/ebola/" target="_blank">Science 
		Magazine Special Collection: Ebola Virus</a> (freely available research and news 
		articles)
		</p>
                <p>
                NCBI sequence database search, publication list, and genome display:
                <a href="http://www.ncbi.nlm.nih.gov/genome/viruses/variation/ebola/" target="_blank"</a>NCBI Virus Variation Ebolavirus Resource</a>
		</p>
		<p>
		The New England Journal of Medicine resource:
		<a href="http://www.nejm.org/page/ebola-outbreak"
		target="_blank">Ebola Outbreak</a>
		(A collection of articles and other resources on the Ebola
		outbreak, including clinical reports, management guidelines, and
		commentary.)
		</p>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<!-- Ebola Biology block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">

            <div class="bar"><h4 class="title">Ebola Biology</h4></div>
            <div class="content">
		<p>
                Ebola virus is the causative agent of Ebola hemorrhagic fever (EHF), 
                a disease affecting humans and other primates. The incubation period 
                for EHF is 2-21 days and typical early symptoms include fever, chills, 
                malaise, and myalgia, followed by the onset of symptoms indicative of 
                multi-organ stress and subsequent failure. The disease is also characterized 
                by high death rates (as high as 90%) and worse yet, is highly contagious, 
                spreading through direct contact with infected body fluids or skin/mucus membrane 
		contact.
                This perfect storm of conditions make the possibility of a large-scale epidemic
                a very real concern.
		</p>
		<p>
                Ebola virus and the related Marburg virus are members of the family 
                Filoviridae, so named for their filamentous shape. Like other Filoviruses, 
                Ebola is an enveloped, non-segmented, negative-stranded RNA virus. Ebola virus 
                particles have at their core a viral nucleocapsid composed of a helical single 
                stranded RNA genome wrapped around viral proteins NP, VP35, VP30, and L. The 
                nucleocapsid is surrounded by an outer viral envelope studded with viral 
                glycoprotein (GP) spikes, and viral proteins VP40 and VP24 sit between the 
                nucleocapsid and the envelope.
		</p>
		<p>
                The viral life cycle begins with host cell entry through a poorly understood 
		mechanism. Once inside 
                the viral RNA-dependent RNA polymerase (L) binds the 19 kb genome as a complex with 
                other factors and transcribes the negative strand genome into a positive strand 
                mRNA to be translated by the host cell's machinery. The seven genes are ordered in 
		the genome as follows: 3-leader-NP-VP35-VP40-GP/sGP-VP30-VP24-L-trailer-5'. Once the
		concentration of nucleocapsid protein (NP) reaches a sufficient level, the RNA 
		polymerase switches 
                modes to genome replication, producing full-length positive strand genomes to be 
                transcribed into negative orientation. These genomes self assemble with 
                other virus proteins and bud from the host cell, sheathed in host 
                cell membrane, thus completing the cycle.
		</p>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<!--Vaccines panel -->
<a name="vaccines">
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
                <div class="bar"><h4 class="title">Vaccine Development</h4></div>
            <div class="content">
		<p>
                In September 2014, Phase 1 clinical trials of the GlaxoSmithKline ChAd3/EBOV vaccine
                began at the U.S. National Institutes of Health and UK Oxford, and
                a second vaccine (VSV/EBOV, produced by Newlink Genetics)
                was approved for trial by the U.S. FDA.
                If the vaccines are found to be safe, some doses could be available 
                for use by healthcare workers in November.
                <ul>
                <li>
                <a href="http://www.niaid.nih.gov/news/QA/Pages/EbolaVaxQA.aspx" target="_blank">Phase 1 Clinical Trials of NIAID/GSK Investigational Ebola Vaccine</a>
                </li>
                <li>
                <a href="http://www.ox.ac.uk/news/2014-08-28-oxford-lead-ebola-vaccine-trial" target="_blank"> Oxford to Lead Ebola Vaccine Trial</a>
                </li>
                <li>
                <a href="http://investors.linkp.com/releasedetail.cfm?ReleaseID=869082" target="_blank">FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine</a>
                </li>
                </ul>
                Other vaccines have been tested in non-human primates with good results.
                Ebola mutates slower than many viruses (e.g. HIV) and is considered a
                good vaccine target.
                We have collected some review articles and research reports pertaining to 
                Ebola vaccine development here:
                <a
                href="https://docs.google.com/spreadsheets/d/1CeDZQ7MztauDl1c11eAPx6iIUUEIFfQUYBxNHUQ5PhM/pubhtml"
                target="_blank">Ebola Vaccine Development: Scientific References</a>.
                </p>
                A vaccine will do much to slow the spread of this epidemic.  
                After preliminary safety trials the question becomes how fast production can be 
		scaled, which is contingent on funding.
                At this time, GlaxoSmithKline has committed to the production of 10,000 vaccine 
		doses by year's end.
                With the U.S. committing significant federal funds to the fight against Ebola,
                we can hope that vaccines will be available in quantity. 
                From Marie-Paule Kieny, assistant director-general of WHO, who spoke at a press
                conference in Geneva in early September: "There is a tide in the affairs of men,
                and that tide is now."
		</p>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<a name="antibodies">

<!--Treatment research panel -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
            <div class="bar"><h4 class="title">Treatment Research</h4></div>
            <div class="content">



		<p>
                Multiple therapeutic approaches for Ebola treatment are under active development.
                References for three close to field use as of September 2014 are listed below.
                See also the <a href="http://www.cdc.gov/vhf/ebola/outbreaks/guinea/qa-experimental-treatments.html" target="_blank">CDC Questions and Answers on Experimental Treatments and Vaccines for Ebola</a>.
		

 		<p>
		<em> Lamivudine </em>: A nucleoside analog reverse transcriptase inhibitor being sold across Africa as an HIV drug.  It has shown remarkable efficacy against the Ebola virus.   
		<ul>
		<li> A CNN release covering the issue : <a href="http://www.cnn.com/2014/09/27/health/ebola-hiv-drug/" target = "_blank" > Lamivudine usage with Ebola patients </a>
		</li>
		<li> An online article discussing the issue : <a href="http://allafrica.com/stories/201409292050.html" target = "_blank" > Lamivudine usage decreases Ebola's virulence </a>
		</li>
		<li> General Information : <a href="http:en.wikipedia.org/wiki/Lamivudine" target = "_blank" > Lamivudine </a>
		</li>
                </ul>
		</p>


		<p>
		<em> AVI-7537 </em>: A drug designed to inhibit the synthesis of nucleocapsid proteins by Sarepta Therapeutics. 
		<ul>
		<li> Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-based therapeutics.
		<a href="http://www.sarepta.com/pipeline/avi-7288-marburg" target = "_blank" > Sarepta Theratpeutics documentation on the drug </a>
		</li>
		</ul>
		</p>

		<! -- first classification of treatments, broad-spectrum small molecule anti -viral> 
                <p>
                <em>Broad-spectrum small molecule anti-viral</em>: Inhibition of viral RNA polymerase by other nucleoside analogues
                <ul>
		<! -- A single reference in this classification of treatments>
                <li>
                Warren et al., Nature (2014): <a href="http://www.nature.com/nature/journal/v508/n7496/full/nature13027.html" target="_blank">Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</a> PMID:24590073.
                </li>
                <li>
                Andreas et al., Antiviral Chemistry (2013): <a href="http://www.researchgate.net/publication/236603294_Retinazone_inhibits_certain_blood-borne_human_viruses_including_Ebola_virus_Zaire" 
		target="_blank">Retinazone inhibits certain blood-borne human viruses inclding Ebola virus Zaire</a> .
                </li>
                
		<li>
                Biocryst Pharmaceuticals: <a href="http://www.biocryst.com/bcx_4430" target="_blank">BCX4430 information page</a>
                </li>
                <li>
                Julander et al., 2nd Antivirals Congress (2012): <a href="http://www.biocryst.com/PDFs/BCX4430_2ndAntiviralsCongressPresentation11Nov12FINAL.pdf" target="_blank">BCX4430, an Adenosine Analog, with Potent Activity Against Yellow Fever  Virus in a Hamster Model</a>
                </li>
                </ul>
                </p>
                <! ending of treatment sub section> 


		<p>
                <em>RNA interference</em>: Combination of siRNAs targeting Ebolavirus RNA polymerase and other proteins (e.g. VP24 and VP35)
                </p>
                <ul>
                <li>
                Geisbert et al., Lancet (2010): <a href="http://www.ncbi.nlm.nih.gov/pubmed/20511019" target="_blank">Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study</a>. PMID:20511019.
                </li>
                <li>
                Tekmira Pharmaceuticals, Press Release (Sept. 22, 2014): <a href="http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=871918" target="_blank">Tekmira Establishes Regulatory Framework for Emergency Use of TKM-Ebola</a>.
                </li>
                </ul>

                <p>
                <em>Immunologic</em>: Cocktail of neutralizing antibodies specific for Ebolavirus surface glycoprotein
                <ul>
		<li>
		Qiu et al., Nature (2014): <a href="http://www.ncbi.nlm.nih.gov/pubmed/25171469"
                target="_blank">Reversion of advanced Ebola virus disease in nonhuman primates with 
		ZMapp</a> 
                [<a href="http://www.nature.com/nature/journal/vnfv/ncurrent/pdf/nature13777.pdf"
                target="_blank">PDF</a>] PMID:25171469.
		</li>
                <li>
                Mapp Pharmaceutical: <a href="http://www.mappbio.com/" target="_blank">ZMapp information pages</a>
		</li>
                <li>
                <a href="http://en.wikipedia.org/wiki/ZMapp" target="_blank">Wikipedia ZMapp page</a>
                </li>
                </ul>
		<b>
                Additional references related to Ebola antibody-based therapeutics are listed at: </b> 
                <a href="antibodyResources.html" target="_blank">UCSC Ebola Genome Portal: Antibody Resources</a>.
		</p>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>



<!-- PR Links block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">

            <div class="bar"><h4 class="title">General Interest Links</h4></div>
            <div class="content">
		<p>
                <a href="http://www.youtube.com/watch?v=qTcfnTISMDk"
		target="_blank">NOVA: Ebola, The Plague Fighters</a> (1995)
		</p>
		<p>
		<a href= "https://www.youtube.com/watch?v=jTF7i6OBGQk"
		target="_blank">Fighting to Contain Sierra Leone's Ebola Epidemic</a> (2014)
		</p>
                <p>
		<a href= "https://www.youtube.com/watch?v=l0EBQKdQyyM" 
		target="_blank">A Popular Song in Africa about Ebola (2014)</a> 
                </p>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>
            </table>
</body>
</html>
